Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Ironwood Pharmaceuticals Inc

IRWD
Current price
10.53 USD +0.23 USD (+2.23%)
Last closed 10.3 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 1 608 128 640 USD
Yield for 12 month -12.25 %
Week
Month
Year
IRWD
21.11.2021 - 28.11.2021

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Address: 100 Summer Street, Boston, MA, United States, 02110

Analytics

WallStreet Target Price

17.4 USD

P/E ratio

Dividend Yield

6.68 %

Current Year

+410 596 000 USD

Last Year

+413 753 000 USD

Current Quarter

+113 739 000 USD

Last Quarter

+107 382 000 USD

Current Year

+410 596 000 USD

Last Year

+413 753 000 USD

Current Quarter

+113 739 000 USD

Last Quarter

+107 382 000 USD

Key Figures IRWD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 234 392 000 USD
Operating Margin TTM 42.74 %
PE Ratio
Return On Assets TTM 18.62 %
PEG Ratio -0.26
Return On Equity TTM -739.27 %
Wall Street Target Price 17.4 USD
Revenue TTM 432 380 992 USD
Book Value -2.07 USD
Revenue Per Share TTM 2.79 USD
Dividend Share
Quarterly Revenue Growth YOY 4.7 %
Dividend Yield 6.68 %
Gross Profit TTM 366 331 000 USD
Earnings Share -6.18 USD
Diluted Eps TTM -6.18 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -68.5 %
Profit Margin -220.24 %

Dividend Analytics IRWD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IRWD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 6.68 %
Last Split Factor 1194:1000
Payout Ratio
Last Split Date 02.04.2019
Dividend Date

Stock Valuation IRWD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 12.3305
Enterprise Value Revenue 5.1756
Price Sales TTM 3.7192
Enterprise Value EBITDA -2.515
Price Book MRQ 2.5899

Financials IRWD

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IRWD

For 52 weeks

8.08 USD 12.66 USD
50 Day MA 9.46 USD
Shares Short Prior Month 17 389 070
200 Day MA 10.19 USD
Short Ratio 7.78
Shares Short 17 153 923
Short Percent 17.92 %